Cellartis, Novo, Lund University in $125M Diabetes Stem Cell Pact
Stem cell science specialist Cellartis AB could earn as much as 100 million (US$125 million) in development and sales milestones from a cell therapy collaboration in diabetes with Novo Nordisk A/S and Lund University in Sweden. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.